Yanan Zhu
Stock Analyst at Wells Fargo
(1.28)
# 3,628
Out of 5,182 analysts
83
Total ratings
35.21%
Success rate
-11.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Overweight | $15 → $60 | $17.16 | +249.65% | 7 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $12 → $15 | $13.13 | +14.24% | 8 | Mar 3, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $45 → $38 | $23.23 | +63.58% | 8 | Feb 27, 2026 | |
| ACLX Arcellx | Downgrades: Equal-Weight | $115 | $114.77 | +0.20% | 1 | Feb 23, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $40 → $50 | $47.58 | +5.09% | 3 | Feb 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $4.37 | +151.72% | 4 | Jan 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $100 | $74.79 | +33.71% | 4 | Jan 5, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $8.03 | +149.07% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.67 | +49.81% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $32.99 | +36.40% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $1.35 | +788.89% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.22 | +104.92% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.41 | +254.61% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $3.43 | +308.16% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $24.66 | +183.86% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.96 | +152.53% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $49.51 | +31.29% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.69 | +348.43% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.30 | +1,232.89% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.93 | +15,258.36% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $746.75 | -56.34% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.20 | +586.27% | 2 | Oct 29, 2020 |
uniQure
Mar 9, 2026
Upgrades: Overweight
Price Target: $15 → $60
Current: $17.16
Upside: +249.65%
Intellia Therapeutics
Mar 3, 2026
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $13.13
Upside: +14.24%
Sarepta Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $45 → $38
Current: $23.23
Upside: +63.58%
Arcellx
Feb 23, 2026
Downgrades: Equal-Weight
Price Target: $115
Current: $114.77
Upside: +0.20%
Spyre Therapeutics
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $50
Current: $47.58
Upside: +5.09%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $4.37
Upside: +151.72%
Ionis Pharmaceuticals
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $74.79
Upside: +33.71%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $8.03
Upside: +149.07%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.67
Upside: +49.81%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $32.99
Upside: +36.40%
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.35
Upside: +788.89%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.22
Upside: +104.92%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.41
Upside: +254.61%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $3.43
Upside: +308.16%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $24.66
Upside: +183.86%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.96
Upside: +152.53%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $49.51
Upside: +31.29%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $6.69
Upside: +348.43%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.30
Upside: +1,232.89%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.93
Upside: +15,258.36%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $746.75
Upside: -56.34%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.20
Upside: +586.27%